ECE2009 Poster Presentations Neuroendocrinology, Pituitary and Behaviour (74 abstracts)
Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly
Antonio Bianchi 1 , Gherardo Mazziotti 2 , Laura Tilaro 1 , Vincenzo Cimino 1 , Teresa Porcelli 1 , Marilda Mormando 1 , Linda Tartaglione 1 , Alfredo Pontecorvi 1 , Andrea Giustina 2 & Laura De Marinis 1
1Department of Endocrinology, School of Medicine, Catholic University, Rome, Italy; 2Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy.
Clinical trials have demonstrated that pegvisomant therapy is highly efficacious, normalizing serum IGF-I levels in the majority of patients with acromegaly. Multiple factors could influence the dose of pegvisomant required to normalize IGF-I, that ranging from 10 to 40 mg/day. However, the determinants of this variability are unknown and, to date, there is no specific recommendation to adjust the dose to the type of patient. Lack of exon 3 of the Growth Hormone receptor (d3-GHR) has been associated with increased responsiveness to GH therapy and with a more morbid acromegalic clinical and biochemical picture. Aim of our study was to assess whether the presence of polymorphism of GH receptor may have a role in predictive dose regimen and responsivity to pegvisomant in acromegaly. We studied a cohort of 19 acromegalic patients with active disease after unsuccessful neurosurgery and somatostatin analogs therapy. All patients started treatment with pegvisomant at 10 mg daily and then increased during a 12-months follow-up until normalize IGF-I levels. The genotype of the GH receptor was determined from peripheral blood. The patients carriers of d3-GHR genotype required a significant lower dose and shorter treatment time to normalize IGF-I. In conclusion, we demonstrated that in acromegaly the GHR genotype could be useful in predicting dose and individual response to pegvisomant in acromegaly.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more